Replies to post #369144 on Amarin Corp Plc (AMRN)

[Whalatane]

Ralphey R U serious ?
U don’t like the mgt so you stop prescribing the drug ? …even for your secondary prevention patients in R-IT profile

So if Denner engineered a sale to NVS for say $9 a share , U would start prescribing V again ?

Do you know if the journal U wanted to publish in would even accept your article?
Have you ever been published before ?
Ever written about a drug when U don’t own stock or have any financial interest in the Co that produced the drug ?

Did U even send AMRN an example of previously published work ?

Think about your idea of not prescribing a drug because you’re unhappy with the company’s stock price .

Kiwi

[The Irishman]

Ralphey…I find your comments troubling. I retired from the pharmaceutical business back in 2019. Your comment regarding how you have stopped prescribing Vascepa reminds me of a small handful of clinicians over the years that did the same thing. They would stop prescribing a drug and even tak patients off because of something that the rep did, said etc, etc… The sad thing, the medications helped their patients.
This behavior was most frustrating for my managers and their sales reps.
Obviously you are free to do whatever you like. Stop prescribing, sell the stock, help yourself. Having said that, why did you prescribe in the first place? Did you believe in the drug? Was your motivation more around contributing to the volume in order to boost share value?
This whole experience has been positive and frustrating, mostly frustrating for all of us. If I may guess, I say your comments are out of frustration, which is understandable. If you wanted to write an article about your patients experience with Vascepa, then I presume you observed efficacy and positive patient outcomes. In the end, I have no doubt that you will do the right thing as you work to help your patients.

Be well

[shadolane]

That's unbelievable that they didn't respond to your offer.

To either take you up on it or explain why they couldn't.

I mentioned in a previous post that I wrote a fairly blunt email to IR and of course got no response.

I'm sure others have experienced the same thing.

Maybe their recently invested heavy weight will be able to get there attention.